英夫利西单抗治疗克罗恩病中免疫平衡及细胞因子的变化和意义

Alterations and Significance of Cytokines and Immune Balance in Patients of Crohn Disease Following Infliximab Therapy

生物制剂英夫利西(IFX)单抗被广泛用于治疗克罗恩病(CD)。它是一种嵌合型单克隆抗体,可靶向CD发病机制中起重要作用的促炎细胞因子——肿瘤坏死因子α(TNF-α),IFX通过中和巨噬细胞和T细胞表面的TNF-α发挥治疗作用的同时,机体的Th1和Th2等细胞因子以及免疫平衡也存在着相应的变化。现就上述变化及其与CD治疗中临床应答的关系进行综述。

Biologic agent infliximab（IFX）is applied to treat Crohn disease（CD）widely at present,which is a chimeric（human-mouse）monoclonal antibody targeted at tumor necrosis factor-α（TNF-α）,a proinflammatory cytokine important in the pathogenesis of CD.IFX works by neutralization of tumor necrosis factor-α on macrophage and T-cell surfaces and results in a variety of changes of Th1 and Th2 cytokines and the immune balance in CD concurrently.Here is to make a review on the relationship between IFX application and its therapeutic effects and the corresponding alterations of immune system in CD patients.